CompletedPhase 1NCT04267497

Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study)

Studying Aspergillosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Principal Investigator
Sonsoles Sancho
President of CEIC Hospital Ramon y Cajal
Intervention
Amphotericin B Liposomal 50 MG(drug)
Enrollment
13 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2022

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04267497 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis →

← Back to all trials